Chris Ryan / iStockphoto.com
A jury has said that Flexus Biosciences, a company owned by Bristol-Myers Squibb (BMS), does not need to pay damages despite being liable for trade secrets misappropriation.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bristol-Myers Squibb, Flexus Biosciences, Incyte, trade secrets misappropriation, jury trial, ICO-1, oncology, cancer research and development